Please Wait.....
Report
Glaucoma Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)
Market Report I 2025-07-01 I 134 Pages I Mordor Intelligence
Glaucoma Treatment Market Analysis
The glaucoma treatment market size stood at USD 6.69 billion in 2025 and is projected to reach USD 8.38 billion by 2030, registering a 4.61% CAGR over the forecast period. The market is expanding because the aged share of the world's population is rising rapidly, while earlier and more accurate diagnosis is becoming routine in both developed and emerging health systems. Selective laser trabeculoplasty (SLT) is shifting first-line practice patterns, and sustained-release implants are transforming adherence economics. Meanwhile, artificial-intelligence (AI) screening networks, minimally invasive glaucoma surgery (MIGS) devices and pharmacogenetic tools are creating additional adoption curves that reinforce demand for both procedural and pharmaceutical solutions.
Global Glaucoma Treatment Market Trends and Insights
Increasing prevalence of glaucoma
Glaucoma incidence climbed to 23.46 per 10,000 person-years among adults aged 40-79 in 2024, with rates peaking at 64.36 in the 75-79 cohort. Urbanization-driven myopia now accelerates risk in Asia-Pacific, where projected case counts may reach 80 million by 2040. Sub-Saharan Africa continues to register the highest regional prevalence yet struggles with late-stage presentation that limits therapeutic effectiveness. Collectively, these demographic and epidemiological forces build a sustained demand floor for the glaucoma treatment market.
Rising awareness & screening initiatives
AI-enabled fundus image analysis achieves 93.52% sensitivity and 95% specificity, allowing reliable mass screening in settings where ophthalmologists are scarce. Smartphone-based cameras tethered to offline algorithms support rural outreach programs with minimal connectivity requirements. National tele-ophthalmology platforms aligned with WHO Vision 2020 extend diagnostic reach in low-resource geographies. These initiatives raise detection rates and funnel new patients into the glaucoma treatment market.
Adverse ocular & systemic side-effects
Pharmacovigilance reviews of the FDA Adverse Event Reporting System show conjunctival hyperemia and periorbital pigmentary changes as prominent signals for prostaglandin analogs. Netarsudil's median onset of ocular inflammation occurs within 1 day, with incident rates skewing higher in the older population. Dry-eye disease prevalence among glaucoma patients ranges from 5% to 50% and is frequently aggravated by benzalkonium-chloride preservatives. Systemic beta-blocker exposure can trigger cardiovascular and respiratory complications in susceptible individuals. These safety issues exert downward pressure on the glaucoma treatment market CAGR by driving discontinuations and regulatory scrutiny.
Other drivers and restraints analyzed in the detailed report include:
Technological advancements in ophthalmology / Sustained-release implants improve adherence / Stringent & lengthy regulatory approvals /
For complete list of drivers and restraints, kindly check the Table Of Contents.
Segment Analysis
Open-angle glaucoma commanded 71.51% of the 2024 glaucoma treatment market share, underpinning the dominant clinical focus because most screening programs identify this form earliest. Segment revenues benefit from a full continuum of care, including topical drugs, SLT, MIGS and sustained-release implants that escalate therapy in graduated steps. Over the forecast horizon, incremental uptake of neuroprotective agents is expected to reinforce value capture in this broad indication.
Secondary glaucoma is expanding at a 9.25% CAGR, driven by better recognition of steroid-induced, pseudoexfoliative and trauma-related etiologies. Higher disease complexity often necessitates combination therapy and specialist procedures, generating above-average revenue per patient and boosting the glaucoma treatment market size for advanced segments.
The Glaucoma Treatment Market Report is Segmented by Indication (Open-Angle Glaucoma, Closed-Angle Glaucoma, Secondary Glaucoma, and More), Drug Class (Prostaglandin Analogs, Beta Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).
Geography Analysis
North America generated 37.32% of 2024 sales, reflecting universal insurance coverage for first-line pharmaceuticals and wide procedural reimbursement. SLT adoption is mainstream, and MIGS growth accelerates as Medicare coverage stabilizes, though branded drop volumes are plateauing amid generic erosion. Canada mirrors U.S. practice patterns but exercises tighter cost-effectiveness thresholds, while Mexico's fast-growing private insurance market shifts demand toward premium implants. Overall, the region remains a high-value anchor for the glaucoma treatment market but is not the fastest-growth engine.
Asia-Pacific is projected to deliver an 8.17% CAGR, the highest regional pace, as China liberalizes drug-approval timelines and India scales AI-enabled screening infrastructure. Japan sustains MIGS uptake through robust post-marketing surveillance, whereas South Korea's national-insurance reimbursement unlocks early adoption of sustained-release devices. Australia demonstrates the template for primary-care AI triage, which is expected to ripple through other health systems. The region's mixture of high unmet need and accelerating technology adoption underpins its outsized contribution to future glaucoma treatment market growth.
Europe delivers steady growth through universal access and strong preference for preservative-free formulations. National payers encourage cost-effective SLT and generic options but also reimburse MIGS when incremental evidence supports long-term value. The Middle East is allocating oil-driven health budgets to expand ophthalmology centers, while Sub-Saharan Africa's high prevalence collides with fiscal constraints, limiting penetration of premium implants despite international aid programs. South America advances selectively: Brazil's public system validated SLT cost-effectiveness, and private chains are testing sustained-release implants.
List of Companies Covered in this Report:
Aerie Pharmaceutical / Abbvie / Akorn / Alcon / Bausch + Lomb / Glaukos / Inotek (Rocket) / Ivantis / Johnson&Johnson / Merck / New World Medical / Nicox / Novartis / Pfizer / Santen / Sun Pharmaceuticals Industries / Teva Pharmaceutical Industries / Valeant (Bausch Health) / GlenmarkPharmaceuticals / Acadia Pharmaceuticals /
Additional Benefits:
The market estimate (ME) sheet in Excel format /
3 months of analyst support /
1 Introduction
1.1 Study Assumptions & Market Definition
1.2 Scope of the Study
2 Research Methodology
3 Executive Summary
4 Market Landscape
4.1 Market Drivers
4.1.1 Increasing Prevalence Of Glaucoma
4.1.2 Rising Awareness & Screening Initiatives
4.1.3 Technological Advancements In Ophthalmology
4.1.4 Sustained-Release Implants Improve Adherence
4.1.5 Adoption Of Minimally Invasive Glaucoma Surgery (MIGS) Devices
4.1.6 Pharmacogenetic-Led Precision Therapy
4.2 Market Restraints
4.2.1 Adverse Ocular & Systemic Side-Effects
4.2.2 Stringent & Lengthy Regulatory Approvals
4.2.3 Reimbursement Gaps For Premium Implants & MIGS
4.2.4 SLT & Laser Therapies Cannibalising Drug Demand
4.3 Porter's Five Forces
4.3.1 Threat of New Entrants
4.3.2 Bargaining Power of Buyers
4.3.3 Bargaining Power of Suppliers
4.3.4 Threat of Substitute Products
4.3.5 Intensity of Competitive Rivalry
5 Market Size & Growth Forecasts (Value, USD)
5.1 By Indication
5.1.1 Open-Angle Glaucoma
5.1.2 Closed-Angle Glaucoma
5.1.3 Secondary Glaucoma
5.1.4 Congenital Glaucoma
5.1.5 Others
5.2 By Drug Class
5.2.1 Prostaglandin Analogs
5.2.2 Beta Blockers
5.2.3 Alpha Agonists
5.2.4 Carbonic Anhydrase Inhibitors
5.2.5 Fixed-Dose Combinations
5.2.6 Rho-Kinase / NO-Donating PGAs
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 South Korea
5.3.3.5 Australia
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 Competitive Landscape
6.1 Market Concentration
6.2 Market Share Analysis
6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
6.3.1 Aerie Pharmaceuticals
6.3.2 AbbVie (Allergan)
6.3.3 Akorn, Inc.
6.3.4 Alcon Inc
6.3.5 Bausch + Lomb
6.3.6 Glaukos
6.3.7 Inotek (Rocket)
6.3.8 Ivantis
6.3.9 Johnson & Johnson
6.3.10 Merck & Co. Inc
6.3.11 New World Medical
6.3.12 Nicox
6.3.13 Novartis AG
6.3.14 Pfizer Inc
6.3.15 Santen
6.3.16 Sun Pharma
6.3.17 Teva
6.3.18 Valeant (Bausch Health)
6.3.19 Glenmark
6.3.20 Acadia Pharmaceuticals
7 Market Opportunities & Future Outlook
7.1 White-space & Unmet-need Assessment
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security